CA 15-3 as a tumor marker in gynecological malignancies

G Scambia, Giovanni Scambia, Benedetti Panici P, P. Benedetti Panici, G. Baiocchi, Baiocchi G, L. Perrone, Perrone L, Greggi S, Stefano Greggi, S Greggi, Stefano Mancuso, Mancuso S, S Mancuso
Gynecologic Oncology · 1988 · vol. 30(2) , pp. 265–273 · doi:10.1016/0090-8258(88)90032-7 · PMID:3163666 · W2016682363
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This review analyzes the utility and limitations of CA 15-3 as a tumor marker across various gynecological cancers.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Serum levels of CA 15-3 were measured in 778 samples from 270 patients with benign and malignant gynecological conditions. Malignant tumors were present in 180 patients including 58 cases with cancer of the ovary, 47 of the endometrium, 61 of the cervix, and 14 of the vulva. The 90 cases with benign conditions included 24 patients with ovarian tumors, 28 with fibromyomatosis, 18 with endometriosis, and 20 with endometrial hyperplasia. Of 180 cancer patients, CA 15-3 serum levels were elevated (greater than 30 U/ml) in 74 cases (41%) and the frequency of abnormal marker values increased with clinical stage. Of 90 patients with benign conditions, high CA 15-3 levels were found in 5 cases (6%) with benign ovarian tumors. Elevated levels of the marker were most commonly seen in ovarian cancer patients (71%). In endometrial, cervical, and vulvar cancer abnormal CA 15-3 values occurred in 32, 26, and 14%, respectively. In endometrial cancer the percentage of positive marker levels increased with more infiltrating and/or less differentiated tumors. A positive correlation was found between residual tumor after surgery and CA 15-3 levels. Serial measurements in sera of patients who underwent chemotherapy showed a good correlation with response to treatment. CA 15-3 values were correlated with clinical course of disease in 87% of cases.

My notes (saved in your browser only)

MeSH descriptors

Antigens, Neoplasm Biomarkers, Tumor Genital Neoplasms, Female Adolescent Adult Antibodies, Monoclonal Antigens, Neoplasm Antigens, Tumor-Associated, Carbohydrate Biomarkers, Tumor Female Genital Neoplasms, Female Genital Neoplasms, Female Genital Neoplasms, Female Humans Membrane Glycoproteins Membrane Glycoproteins Middle Aged Mucin-1 Neoplasm Staging Postoperative Period

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (25)

Source provenance

europepmc
last seen: 2026-08-22T06:09:51.966504+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:09:20.810540+00:00
unpaywall
last seen: 2026-08-22T06:23:50.750314+00:00
License: CC0 · commercial use OK